BMS-986094 + daclatasvir + ribavirin

BMS-986094 + daclatasvir + ribavirin is an investigational combination regimen that was studied for the treatment of chronic hepatitis C virus (HCV) infection. - **BMS-986094** is a nucleotide analogue prodrug that acts as a nonstructural 5B (NS5B) RNA-dependent RNA polymerase inhibitor, directly targeting HCV replication. - **Daclatasvir** is a small-molecule inhibitor targeting HCV nonstructural protein 5A (NS5A), thus interfering with viral RNA replication and virion assembly. - **Ribavirin** is a nucleoside analogue with broad-spectrum antiviral activity, most commonly used as an adjunct to boost antiviral efficacy by inducing lethal mutagenesis in viral RNA genomes. BMS-986094 was discontinued in clinical development due to severe cardiac and renal toxicity, including heart failure and renal impairment, with several cases of hospitalization and at least one reported death[1][2][3][5][7]. Daclatasvir and ribavirin remained in clinical use for HCV in various other combinations, but this specific triple combination was not approved or advanced following BMS-986094’s safety concerns.